Drugs Made In America Acquisition NT 10-Q for Q3 2025

Rhea-AI Filing Summary

Drugs Made In America Acquisition Corp. (DMAA) has filed a Form 12b-25 to notify the SEC that it will be late filing its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company explains that the financial statements for this quarter were not completed in time to obtain the necessary internal review and required signatures before the normal filing deadline. This notice is intended to provide a short grace period while the report is finalized and formally submitted.

Insights

SEC Reporting and Governance Analyst

Late 10-Q due to incomplete financials; modest negative signal on reporting timeliness, with short expected delay under Rule 12b-25.

Drugs Made In America Acquisition Corp. filed a Form 12b-25 to notify a late Form 10-Q for the period ended September 30, 2025. The company states that its financial statements could not be completed in time to obtain required reviews and signatures before the deadline. By using Rule 12b-25, it indicates an intention to file the delayed quarterly report within the permitted short extension window for a Form 10-Q.

A late filing tied to unfinished financial statements points to pressure on the company’s financial reporting and closing process. Even though Rule 12b-25 offers a procedural remedy, repeated or extended delays can raise questions about internal timetables and coordination with auditors or reviewers. The filing does not describe any specific operational or financial issue causing the delay, so the only confirmed issue is timing of preparation and review.

The key near-term item is whether the Form 10-Q is actually filed within the allowed extension period counted from the original due date. That filing will show whether there are disclosed changes in results of operations for the quarter ended September 30, 2025 and may provide more context on any challenges tied to preparing the financial statements. Monitoring the company’s ability to meet future periodic filing deadlines over the next few reporting cycles can help gauge whether this delay is isolated or recurring.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 09:36 PM Learn about SEC filing dates

FAQ

Why did DMAA file a Form 12b-25 late filing notice?

DMAA filed Form 12b-25 because its Quarterly Report on Form 10-Q for the period ended September 30, 2025 could not be completed in time to obtain all required reviews and signatures before the original due date.

Which DMAA filing is affected by the late filing notice?

The late filing notice relates to DMAA’s Form 10-Q for the quarterly period ended September 30, 2025.

What main reason does DMAA give for the late Form 10-Q?

DMAA states that the underlying financial statements for the quarter ended September 30, 2025 could not be completed in sufficient time to allow the necessary review and obtain required signatures before the report’s due date.

Does DMAA’s Form 12b-25 discuss changes in results of operations?

The Form 12b-25 includes a standard question about whether a significant change in results of operations is expected in the upcoming Form 10-Q, but the provided content does not show which response DMAA selected.

Who signed DMAA’s late filing notice for the September 30, 2025 quarter?

The notification was signed on behalf of DMAA by Lynn Stockwell, who is identified as the company’s Chief Executive Officer.

What period does DMAA’s delayed Form 10-Q cover?

The delayed Form 10-Q that DMAA references in its Form 12b-25 covers the quarterly period ended September 30, 2025.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

	NOTIFICATION OF LATE FILING	SEC FILE NUMBER
		001-42467
		CUSIP NUMBER
		G2847J 104

(Check One):	☐ Form 10-K	☐ Form 20-F	☐ Form 11-K	☒ Form 10-Q	☐ Form 10-D	☐ Form N-CEN
	☐ Form N-CSR

For Period Ended: September 30, 2025 

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q

For the Transition Period Ended: _______________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

Drugs Made In America Acquisition Corp.

Full Name of Registrant

Former Name if Applicable

1 East Broward Boulevard, Suite 700

Address of Principal Executive Office (Street and Number)

Fort Lauderdale, FL 33301

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

We could not timely file our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion prior to the due date of the report.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Lynn Stockwell		(954)		870-3099
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).	☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?	☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Drugs Made In America Acquisition Corp.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date : November 14, 2025	By:	/s/ Lynn Stockwell
		Name:	Lynn Stockwell
		Title:	Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

3